Navigation Links
BIO 2008: Germany on Cutting Edge in Biomanufacturing
Date:6/18/2008

SAN DIEGO, California, June 18 /PRNewswire/ -- Germany is on the cutting edge in biotechnology R&D and is a top player in large- and clinical-scale production. Companies located in Germany are poised to profit from the latest developments in biomanufacturing. These were the results of an expert panel, at the BIO International Convention (BIO 2008) in San Diego, California on June 18th. Invest in Germany co-chaired the panel along with the CEO of a major transatlantic biotech consultancy.

Dr. Barbara Esch opened the discussion, entitled "Biomanufacturing Solutions: Case Studies from Germany." She is responsible for the business development of biopharmaceuticals in the Corporate Division Biopharmaceuticals at the Boehringer Ingelheim GmbH in Ingelheim, Germany. Her presentation provided an overview of the biotechnology market in Germany, and offered examples of leading investment successes in Germany. Dr. Wiltrud Treffenfeldt, Director of Bioprocess Development, Dow AgroSciences LLC, discussed why the German contract manufacturing industry is uniquely positioned to create sustainable value in biopharmaceutical development and supply. Dr. Uwe Marx, Chief Scientific Officer (CSO) of Probiogen, a Berlin-based company that specializes in mammalian cell engineering and cell culture, discussed clinical biomanufacturing and how it serves the diverse needs of his company's client base.

Lastly Dr. Uwe Gottschalk, Vice President of Purification Technologies at Sartorius AG, talked about his perception of the current trends in biomanufacturing from the focus of an internationally leading process technology provider.

Angelika Geiger, Director of Invest in Germany's San Francisco office, and Steven Dickman, CEO of CBT Advisors chaired the panel. CBT Advisors is an international strategic consultancy with a focus on European and American biotech companies. Mr. Dickman also has experience in Germany. He previously did biochemical research at the German Cancer Research Center and served as correspondent for the journal Nature in Germany.

Invest in Germany is the inward investment promotion agency of the Federal Republic of Germany. It provides investors with comprehensive support from site selection to the implementation of investment decisions. Invest in Germany is at booth 711 throughout BIO 2008.

Eva Henkel

Invest in Germany

Phone: +49-30-200099-173

email: henkel@invest-in-germany.com

http://www.invest-in-germany.com


'/>"/>
SOURCE Invest in Germany
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
2. Commencement 2008: Student innovation could improve data storage, magnetic sensors
3. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
4. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
5. The World Economic Forum Announces Technology Pioneers 2008: Mondobiotech Selected
6. Pharmaxis Aridol Authorised for Sale in Germany
7. World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment
8. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
9. Germany Hosts World Leading Medical Industry Fair
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent Office (EPO) ... of three finalists for the European Inventor Award 2016 in the category "Non-European countries." ... announced at a ceremony in Lisbon on June 9th. , The human capacity to ...
(Date:4/26/2016)... ... 2016 , ... Mr. Palmer created the RPO business for Ceridian and lead ... managed services contract in the U.S. intelligence community with The SI (a Lockheed Martin ... Younger, founder of Accolo. “We are growing and his experience guiding our expansion ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a ... round of financing. Healthy investor interest drove significant oversubscription of the original $1.5M ... known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, ...
(Date:4/26/2016)... and MIAMI , ... prize recognizes the innovation capabilities of Norma,s R&D ... benefit patients and laboratory diagnostics globally. ... Norma Instruments , an innovative technology ... the field of hematology, announced today that it ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):